Aims

To support the free and open dissemination of research findings and information on alcoholism and alcohol-related problems. To encourage open access to peer-reviewed articles free for all to view.

For full versions of posted research articles readers are encouraged to email requests for "electronic reprints" (text file, PDF files, FAX copies) to the corresponding or lead author, who is highlighted in the posting.

___________________________________________

Wednesday, March 7, 2012

Press Release - Data presented at the 2012 European Congress of Psychiatry on Selincro™ demonstrate that alcohol dependent patients were able to red




  • Phase III clinical data showed that patients treated with Selincro (nalmefene) were able to reduce their total alcohol consumption by 66% on average after six months of treatment
  • The effect is maintained and even improved after one year of treatment
  • Selincro has been shown to be safe and well tolerated
  • Selincro has a significant potential for helping individuals with alcohol dependence in reducing their alcohol consumption
  • Selincro is the first medicine aimed for the reduction of alcohol consumption in patients with alcohol dependence and it is currently undergoing regulatory review in Europe
  • Patients with alcohol dependence are currently both underdiagnosed and undertreated indicating a need for new treatment approaches
  • Alcohol dependence is one of the most burdensome diseases ranked as number 9 according to WHO
  • The risk for all types of harms is lessened, and for most conditions, reversed with a reduction of alcohol consumption, both the overall volume of consumption and consumption at any one time10

H. Lundbeck A/S (Lundbeck) today announced the results of the clinical phase III programme of Selincro™ (nalmefene), an investigational compound for the treatment of alcohol dependence, at the 20th European Congress of Psychiatry (EPA) in Prague, Czech Republic. The symposium presentation included results from the three placebo-controlled clinical phase III studies (ESENSE 1, ESENSE 2 and SENSE). In addition, the ESENSE 1 study was presented as a poster (poster no. 710) by Prof. Dr. Karl Mann et al. Further details of the ESENSE 2 and SENSE studies will be presented at the Annual Research Society on Alcoholism (RSA) Scientific Meeting in San Francisco in June.

The results of the three studies support the efficacy and tolerability of Selincro in reducing alcohol consumption in patients with alcohol dependence. > > > > Read More

at